Post Resch Tallon Group Inc. Buys New Position in Syndax Pharmaceuticals, Inc. $SNDX

Post Resch Tallon Group Inc. purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 25,800 shares of the company’s stock, valued at approximately $397,000.

Several other large investors also recently modified their holdings of SNDX. Lazard Asset Management LLC acquired a new position in shares of Syndax Pharmaceuticals during the 2nd quarter valued at $66,000. Tower Research Capital LLC TRC increased its stake in Syndax Pharmaceuticals by 103.3% in the second quarter. Tower Research Capital LLC TRC now owns 8,480 shares of the company’s stock valued at $79,000 after purchasing an additional 4,308 shares in the last quarter. Prudential Financial Inc. acquired a new position in shares of Syndax Pharmaceuticals during the second quarter valued at about $97,000. Raymond James Financial Inc. bought a new position in shares of Syndax Pharmaceuticals during the 2nd quarter worth about $103,000. Finally, Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Syndax Pharmaceuticals in the 3rd quarter valued at about $212,000.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SNDX. BTIG Research reaffirmed a “buy” rating and set a $56.00 price target on shares of Syndax Pharmaceuticals in a research note on Tuesday, December 9th. UBS Group upped their target price on Syndax Pharmaceuticals from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Wall Street Zen cut Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Barclays boosted their price target on shares of Syndax Pharmaceuticals from $22.00 to $35.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Syndax Pharmaceuticals in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $37.20.

Syndax Pharmaceuticals Trading Down 0.5%

NASDAQ SNDX opened at $21.25 on Wednesday. The company has a current ratio of 4.64, a quick ratio of 4.42 and a debt-to-equity ratio of 2.78. The business has a fifty day simple moving average of $20.64 and a 200 day simple moving average of $16.84. Syndax Pharmaceuticals, Inc. has a 12 month low of $8.58 and a 12 month high of $22.73. The firm has a market capitalization of $1.85 billion, a P/E ratio of -5.89 and a beta of 0.46.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its earnings results on Monday, November 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.04. The firm had revenue of $45.87 million during the quarter, compared to analyst estimates of $49.08 million. Syndax Pharmaceuticals had a negative net margin of 279.31% and a negative return on equity of 160.60%. During the same quarter in the prior year, the business posted ($0.98) EPS. The business’s revenue was up 266.4% compared to the same quarter last year. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for the treatment of cancer. Headquartered in Waltham, Massachusetts, the company focuses on small-molecule inhibitors that target key epigenetic and protein interaction pathways. Syndax’s research platform aims to enhance the effectiveness of existing therapies and address high unmet medical needs in oncology.

The company’s lead investigational candidate, entinostat, is a selective class I histone deacetylase (HDAC) inhibitor being evaluated for multiple solid tumor and hematologic indications.